10. HOW does Normax plan to be profitable in the mRNA Vaccine Business?

Normax estimates that the average cost for Normax Vax Factory to manufacture mRNA Vaccines at large scale for infectious diseases is about $2.00 per dose, or less.

Normax plans to sell our mRNA Vaccines for infectious diseases on large scale advance purchase agreements (APA) with customers at about $4.00 per dose.

This represents a gross profit on sales of 100%.

While big pharma charges anywhere from $8 to $35 per COVID vaccine dose, Normax believes that a 100% gross profit mark-up on sales represents a sustainable and profitable high-impact business for our investors.

The first mRNA Vaccines currently in early stage research and development by Normax are for:

  • SARS-CoV-2 with a “Universal Covid Vaccine” (UCV)
  • Tuberculosis (TB)
  • Human Immunodeficiency Virus (HIV)
  • Malaria

In theory, mRNA vaccines by Normax could save-a-life for less than the cost of a hamburger.

By |2022-09-02T07:25:25+00:00August 31, 2022||Comments Off on 10. HOW does Normax plan to be profitable in the mRNA Vaccine Business?

About the Author:

Go to Top